Omnicell (NASDAQ:OMCL) Posts Earnings Results

Omnicell (NASDAQ:OMCL) announced its earnings results on Thursday. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12), Zacks reports. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell updated its Q1 2025 guidance to 0.150-0.250 EPS and its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Stock Performance

Shares of OMCL opened at $40.16 on Friday. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 148.75, a P/E/G ratio of 26.98 and a beta of 0.78. The business’s fifty day simple moving average is $44.34 and its two-hundred day simple moving average is $43.20. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on OMCL. Craig Hallum raised their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday. Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $52.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.